Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Chordoma: The Quest for Better Treatment Options

Chordoma: The Quest for Better Treatment Options Chordoma is an extremely rare cancer, with an incidence of about one case per million persons per year in the USA and Europe (about 300 and 450 cases per year, respectively). The estimated median overall survival of patients with chordoma is approximately 6–7 years, yielding a rough estimate of chordoma prevalence at about 2000 in the USA and 3000 in Europe. Primary tumor develops along the axial spine between the clivus and sacrum and develops from the residual embryonic notochord. Brachyury (T), a transcription factor required for normal embryonic development, is expressed in the notochord and overexpressed in almost all cases of chordoma. The primary treatment for chordoma is surgical excision with wide local margins, when possible. Radiotherapy also plays a significant role in the adjuvant setting and when surgery is not possible. Unfortunately, in the advanced and/or metastatic setting, where the role of surgery and/or radiation is less clear, treatment options are very limited. To date, there have been no randomized, controlled trials in chordoma that have resulted in defined agents of clinical benefit for systemic treatment. This review briefly describes the natural history and initial treatment of chordoma and focuses on treatment options for advanced disease and potential avenues of research that may lead to improved treatment options in the future. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Chordoma: The Quest for Better Treatment Options

Heery, Christopher
Oncology and Therapy , Volume 4 (1) – Mar 3, 2016
Download PDF
17 pages

Loading next page...
 
/lp/springer-journals/chordoma-the-quest-for-better-treatment-options-HCD2rT0KYc
Publisher
Springer Journals
Copyright
Copyright © 2016 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-016-0016-0
Publisher site
See Article on Publisher Site

Abstract

Chordoma is an extremely rare cancer, with an incidence of about one case per million persons per year in the USA and Europe (about 300 and 450 cases per year, respectively). The estimated median overall survival of patients with chordoma is approximately 6–7 years, yielding a rough estimate of chordoma prevalence at about 2000 in the USA and 3000 in Europe. Primary tumor develops along the axial spine between the clivus and sacrum and develops from the residual embryonic notochord. Brachyury (T), a transcription factor required for normal embryonic development, is expressed in the notochord and overexpressed in almost all cases of chordoma. The primary treatment for chordoma is surgical excision with wide local margins, when possible. Radiotherapy also plays a significant role in the adjuvant setting and when surgery is not possible. Unfortunately, in the advanced and/or metastatic setting, where the role of surgery and/or radiation is less clear, treatment options are very limited. To date, there have been no randomized, controlled trials in chordoma that have resulted in defined agents of clinical benefit for systemic treatment. This review briefly describes the natural history and initial treatment of chordoma and focuses on treatment options for advanced disease and potential avenues of research that may lead to improved treatment options in the future.

Journal

Oncology and Therapy – Springer Journals

Published: Mar 3, 2016

References

  • Chordoma: incidence and survival patterns in the United States, 1973-1995
    McMaster, ML; Goldstein, AM; Bromley, CM; Ishibe, N; Parry, DM
  • Chordoma: the nonsarcoma primary bone tumor
    Chugh, R; Tawbi, H; Lucas, DR; Biermann, JS; Schuetze, SM; Baker, LH
  • Classic chordoma coexisting with benign notochordal cell rest demonstrating different immunohistological expression patterns of brachyury and galectin-3
    Shen, J; Li, CD; Yang, HL
  • Three-dimensional reconstruction of human embryonic notochords: clue to the pathogenesis of chordoma
    Salisbury, JR; Deverell, MH; Cookson, MJ; Whimster, WF
  • Untersuchungen ueber die Entwicklung des Schaedelgrundes
    Virchow, RL
  • Uber die Ecchondosis physaliphora sphenooccipitalis
    Ribbert, H
  • Chordoma: current concepts, management, and future directions
    Walcott, BP; Nahed, BV; Mohyeldin, A; Coumans, JV; Kahle, KT; Ferreira, MJ
  • Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas
    Vujovic, S; Henderson, S; Presneau, N
  • Imaging characteristics of metastatic chordoma
    Kishimoto, R; Omatsu, T; Hasegawa, A; Imai, R; Kandatsu, S; Kamada, T
  • Primary tumors of the sacrum: diagnostic imaging
    Llauger, J; Palmer, J; Amores, S; Bague, S; Camins, A
  • Sacral chordomas: Impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor
    Park, L; Delaney, TF; Liebsch, NJ
  • Predictors of recurrence following resection of intracranial chordomas
    Choy, W; Terterov, S; Kaprealian, TB
  • Chordoma and chondroid neoplasms of the spheno-occiput. An immunohistochemical study of 41 cases with prognostic and nosologic implications
    Mitchell, A; Scheithauer, BW; Unni, KK; Forsyth, PJ; Wold, LE; McGivney, DJ
  • “Dedifferentiated” chordoma. A clinicopathologic and immunohistochemical study of three cases
    Meis, JM; Raymond, AK; Evans, HL; Charles, RE; Giraldo, AA
  • Chordoma with a massive spindle-cell sarcomatous transformation. A light- and electron-microscopic and immunohistological study
    Miettinen, M; Karaharju, E; Jarvinen, H
  • Nuclear brachyury expression is consistent in chordoma, common in germ cell tumors and small cell carcinomas, and rare in other carcinomas and sarcomas: an immunohistochemical study of 5229 cases
    Miettinen, M; Wang, Z; Lasota, J; Heery, C; Schlom, J; Palena, C
  • Brachyury, SOX-9, and podoplanin, new markers in the skull base chordoma vs chondrosarcoma differential: a tissue microarray-based comparative analysis
    Oakley, GJ; Fuhrer, K; Seethala, RR
  • Building a global consensus approach to chordoma: a position paper from the medical and patient community
    Stacchiotti, S; Sommer, J
  • Review of current treatment of sacral chordoma
    Chen, KW; Yang, HL; Kandimalla, Y; Liu, JY; Wang, GL
  • Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers
    Stacchiotti, S; Casali, PG; Lo Vullo, S
  • Operative management of sacral chordoma
    Fuchs, B; Dickey, ID; Yaszemski, MJ; Inwards, CY; Sim, FH
  • Long-term results of Phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas
    DeLaney, TF; Liebsch, NJ; Pedlow, FX
  • High-dose proton-based radiation therapy in the management of spine chordomas: outcomes and clinicopathological prognostic factors
    Rotondo, RL; Folkert, W; Liebsch, NJ
  • Chordoma. A clinicopathologic study of metastasis
    Chambers, PW; Schwinn, CP
  • Chordoma: natural history and results in 28 patients treated at a single institution
    Baratti, D; Gronchi, A; Pennacchioli, E
  • Metastatic disease from spinal chordoma: a 10-year experience
    McPherson, CM; Suki, D; McCutcheon, IE; Gokaslan, ZL; Rhines, LD; Mendel, E
  • CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
    Carroll, M; Ohno-Jones, S; Tamura, S
  • Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta
    Apperley, JF; Gardembas, M; Melo, JV
  • Phase II study of imatinib in advanced chordoma
    Stacchiotti, S; Longhi, A; Ferraresi, V
  • Chordoma: clinical characteristics, management and prognosis of a case series of 25 patients
    Ferraresi, V; Nuzzo, C; Zoccali, C
  • Overexpression of brachyury contributes to tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma
    Du, R; Wu, S; Lv, X; Fang, H; Wu, S; Kang, J
  • The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target
    Shalaby, A; Presneau, N; Ye, H
  • Phase II study on lapatinib in advanced EGFR-positive chordoma
    Stacchiotti, S; Tamborini, E; Lo Vullo, S
  • Response to erlotinib in a patient with treatment refractory chordoma
    Singhal, N; Kotasek, D; Parnis, FX
  • Durable stabilization of three chordoma cases by bevacizumab and erlotinib
    Asklund, T; Sandstrom, M; Shahidi, S; Riklund, K; Henriksson, R
  • Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma
    Hof, H; Welzel, T; Debus, J
  • Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib
    Linden, O; Stenberg, L; Kjellen, E
  • Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)
    Bompas, E; Cesne, A; Tresch-Bruneel, E
  • Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
    Wilhelm, SM; Adnane, L; Newell, P; Villanueva, A; Llovet, JM; Lynch, M
  • Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma
    Chugh, R; Dunn, R; Zalupski, MM
  • Effective use of thalidomide in the treatment of recurrent metastatic chordoma
    Chay, WY; Teo, M; Sittampalam, K; Toh, HC
  • Rare cancer trial design: lessons from FDA approvals
    Gaddipati, H; Liu, K; Pariser, A; Pazdur, R
  • Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study
    Presneau, N; Shalaby, A; Ye, H
  • An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordoma
    Nelson, AC; Pillay, N; Henderson, S
  • T (brachyury) gene duplication confers major susceptibility to familial chordoma
    Yang, XR; Ng, D; Alcorta, DA
  • A common single-nucleotide variant in T is strongly associated with chordoma
    Pillay, N; Plagnol, V; Tarpey, PS
  • The brachyury Gly177Asp SNP is not associated with a risk of skull base chordoma in the Chinese population
    Wu, Z; Wang, K; Wang, L
  • Brachyury expression in extra-axial skeletal and soft tissue chordomas: a marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue
    Tirabosco, R; Mangham, DC; Rosenberg, AE
  • T-box transcription factor brachyury is associated with prostate cancer progression and aggressiveness
    Pinto, F; Pertega-Gomes, N; Pereira, MS
  • Brachyury expression predicts poor prognosis at early stages of colorectal cancer
    Kilic, N; Feldhaus, S; Kilic, E
  • Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer
    Roselli, M; Fernando, RI; Guadagni, F
  • Aberrant expression of the embryonic transcription factor brachyury in human tumors detected with a novel rabbit monoclonal antibody
    Hamilton, DH; Fernando, RI; Schlom, J; Palena, C
  • The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells
    Fernando, RI; Litzinger, M; Trono, P; Hamilton, DH; Schlom, J; Palena, C
  • BRACHYURY confers cancer stem cell characteristics on colorectal cancer cells
    Sarkar, D; Shields, B; Davies, ML; Muller, J; Wakeman, JA
  • The embryonic transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to conventional antitumor therapies
    Huang, B; Cohen, JR; Fernando, RI
  • Cadherins and catenins in clival chordomas: correlation of expression with tumor aggressiveness
    Triana, A; Sen, C; Wolfe, D; Hazan, R
  • Chordoma: an immunohistologic study
    Abenoza, P; Sibley, RK
  • Drugging the undruggable: transcription therapy for cancer
    Yan, C; Higgins, PJ
  • Cancer vaccines targeting the epithelial-mesenchymal transition: tissue distribution of brachyury and other drivers of the mesenchymal-like phenotype of carcinomas
    Hamilton, DH; Litzinger, MT; Fernando, RI; Huang, B; Palena, C
  • The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy
    Palena, C; Polev, DE; Tsang, KY
  • Phase I trial of a yeast-based therapeutic cancer vaccine (GI-6301) targeting the transcription factor brachyury
    Heery, CR; Singh, BH; Rauckhorst, M
  • Attacking malignant cells that survive therapy: exploiting immunogenic modulation
    Hodge, JW; Kwilas, A; Ardiani, A; Gameiro, SR
  • Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing
    Gameiro, SR; Jammeh, ML; Wattenberg, MM; Tsang, KY; Ferrone, S; Hodge, JW
  • Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens
    Gameiro, SR; Ardiani, A; Kwilas, A; Hodge, JW
  • Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma
    Bilusic, M; Heery, CR; Arlen, PM
  • A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer
    Mohebtash, M; Tsang, KY; Madan, RA
  • Cellular localisation of survivin: impact on the prognosis in colorectal cancer
    Ponnelle, T; Chapusot, C; Martin, L
  • Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics
    Mita, AC; Mita, MM; Nawrocki, ST; Giles, FJ
  • Expression of the apoptosis inhibitor protein Survivin in primary laryngeal carcinoma and cervical lymph node metastasis
    Marioni, G; Bertolin, A; Giacomelli, L
  • High nuclear expression of the apoptosis inhibitor protein survivin is associated with disease recurrence and poor prognosis in laryngeal basaloid squamous cell carcinoma
    Marioni, G; Ottaviano, G; Marchese-Ragona, R
  • High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level
    Xu, C; Yamamoto-Ibusuki, M; Yamamoto, Y
  • The significance of Survivin and Nectin-4 expression in the prognosis of breast carcinoma
    Athanassiadou, AM; Patsouris, E; Tsipis, A; Gonidi, M; Athanassiadou, P
  • A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
    Ambrosini, G; Adida, C; Altieri, DC
  • High expression of survivin in sacral chordoma
    Chen, C; Yang, HL; Chen, KW
  • Examination of survivin expression in 50 chordoma specimens—a histological and in vitro study
    Froehlich, EV; Rinner, B; Deutsch, AJ
  • A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma
    Lewis, KD; Samlowski, W; Ward, J
  • Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer
    Giaccone, G; Zatloukal, P; Roubec, J
  • A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer
    Tolcher, AW; Quinn, DI; Ferrari, A
  • microRNAs and cancer: an overview
    Medina, PP; Slack, FJ
  • Differential expression of microRNA (miRNA) in chordoma reveals a role for miRNA-1 in Met expression
    Duan, Z; Choy, E; Nielsen, GP
  • Prognostic significance of miRNA-1 (miR-1) expression in patients with chordoma
    Duan, Z; Shen, J; Yang, X
  • MicroRNA-1 (miR-1) inhibits chordoma cell migration and invasion by targeting slug
    Osaka, E; Yang, X; Shen, JK
  • Integrated miRNA-mRNA analysis revealing the potential roles of miRNAs in chordomas
    Long, C; Jiang, L; Wei, F
  • MicroRNA expression profiling reveals the potential function of microRNA-31 in chordomas
    Bayrak, OF; Gulluoglu, S; Aydemir, E
  • MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET
    Zhang, Y; Schiff, D; Park, D; Abounader, R
  • Overexpression of adenosine deaminase acting on RNA 1 in chordoma tissues is associated with chordoma pathogenesis by reducing miR125a and miR10a expression
    Kuang, L; Lv, G; Wang, B; Li, L; Dai, Y; Li, Y
  • Identification of miR-140-3p as a marker associated with poor prognosis in spinal chordoma
    Zou, MX; Huang, W; Wang, XB; Lv, GH; Li, J; Deng, YW
  • MicroRNA-155 expression is independently predictive of outcome in chordoma
    Osaka, E; Kelly, AD; Spentzos, D
  • Reduced expression of miRNA-1237-3p associated with poor survival of spinal chordoma patients
    Zou, MX; Huang, W; Wang, XB
  • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
    Topalian, SL; Hodi, FS; Brahmer, JR
  • Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
    Topalian, SL; Drake, CG; Pardoll, DM
  • Antagonists of PD-1 and PD-L1 in cancer treatment
    Lipson, EJ; Forde, PM; Hammers, HJ; Emens, LA; Taube, JM; Topalian, SL
  • PD-1 and its ligands in tolerance and immunity
    Keir, ME; Butte, MJ; Freeman, GJ; Sharpe, AH
  • PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment
    Mathios, D; Ruzevick, J; Jackson, CM
  • Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma
    Feng, Y; Shen, J; Gao, Y
  • MGMT gene silencing and benefit from temozolomide in glioblastoma
    Hegi, ME; Diserens, AC; Gorlia, T
  • MGMT promoter methylation status in clival chordoma
    Marucci, G; Morandi, L; Mazzatenta, D; Frank, G; Pasquini, E; Foschini, MP
  • Combined PDGFR and HDAC inhibition overcomes PTEN disruption in chordoma
    Lee, DH; Zhang, Y; Kassam, AB
  • Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma
    Wang, XF; Qian, DZ; Ren, M
  • Epigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cells
    Chun, SM; Lee, JY; Choi, J
  • Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy
    Park, J; Thomas, S; Munster, PN
  • Multifractionated image-guided and stereotactic intensity-modulated radiotherapy of paraspinal tumors: a preliminary report
    Yamada, Y; Lovelock, DM; Yenice, KM